ZyVersa Therapeutics Inc.

Company Profile

ZyVersa Therapeutics Inc. had its IPO on 2022-12-12 under the ticker symbol ZVSA.

The company operates in the Healthcare sector and Biotechnology industry. ZyVersa Therapeutics Inc. has a staff strength of 7 employees.

Stock update

Shares of ZyVersa Therapeutics Inc. opened at $0.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.11 - $0.13, and closed at $0.13.

This is a +15.77% increase from the previous day's closing price.

A total volume of 8,145,052 shares were traded at the close of the day’s session.

In the last one week, shares of ZyVersa Therapeutics Inc. have slipped by -8.87%.

ZyVersa Therapeutics Inc.'s Key Ratios

ZyVersa Therapeutics Inc. has a market cap of $4.34 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months ZyVersa Therapeutics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-16161874. The EBITDA ratio measures ZyVersa Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ZyVersa Therapeutics Inc.’s operating margin was 0% while its return on assets stood at -59.59% with a return of equity of -4011.44%.

In Q2, ZyVersa Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

ZyVersa Therapeutics Inc.’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-7.47 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ZyVersa Therapeutics Inc.’s profitability.

ZyVersa Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

ZyVersa Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$31.99 million

Total Liabilities

$10.48 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

ZyVersa Therapeutics Inc. ended 2025 with $31.99 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.99 million while shareholder equity stood at $20.06 million.

ZyVersa Therapeutics Inc. ended 2025 with $0 in deferred long-term liabilities, $10.48 million in other current liabilities, 2367.00 in common stock, $-86978221.00 in retained earnings and $11.90 billion in goodwill. Its cash balance stood at $228693.00 and cash and short-term investments were $228693.00. The company’s total short-term debt was $59,625 while long-term debt stood at $0.

ZyVersa Therapeutics Inc.’s total current assets stands at $1.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $8.14 million and inventory worth $0.

In 2025, ZyVersa Therapeutics Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, ZyVersa Therapeutics Inc. paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$0.13

52-Week High

$25

52-Week Low

$0.11

Analyst Target Price

$

ZyVersa Therapeutics Inc. stock is currently trading at $0.13 per share. It touched a 52-week high of $25 and a 52-week low of $25. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.18 and 200-day moving average was $0 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.

Around 5443.8% of the company’s stock are held by insiders while 2796.7% are held by institutions.